Literature DB >> 8655710

Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.

R Montironi1, M Valli, G Fabris.   

Abstract

AIMS: To describe the prostatic adenectomy specimens of six patients with symptomatic benign prostatic hyperplasia (BPH) who failed to respond to long term treatment with a 5-alpha-reductase inhibitor, finasteride.
METHODS: Histological sections from six cases of BPH who had been treated with finasteride were investigated. Five patients were prescribed 5 mg finasteride daily for six months and one patient 5 mg daily for 12 months. The patients underwent adenectomy as their urethral obstruction failed to resolve. Twenty cases of untreated BPH served as controls.
RESULTS: In patients taking finasteride for six months the prostatic adenectomy specimens showed a reduction in the size of the prostate and an increase in the stroma:epithelial and stroma:lumen ratios compared with controls. The size of the ducts and acini was not as uniform as in the controls. In particular, some ducts and acini were still lined by a bistratified epithelium similar to that found in controls but lacked undulations at the epithelial border; other ducts/acini were atrophic. Some scattered clusters of small acini with a focally fragmented basal cell layer were observed in two of the five treated cases. One prostatic adenectomy specimen, from the patient treated for one year, showed extensive lobular atrophy and diffuse squamous and transitional cell metaplasia. At the periphery of the transition zone, there was a complex intra-acinar papillary-cribriform proliferation of clear cells without nuclear atypia, similar to clear cell papillary hyperplasia. The periurethral region showed stromal nodules in both patients and controls.
CONCLUSIONS: Morphological evaluation of finasteride treated BPH showed changes in the lobules of the transition zone, but not in the periurethral stroma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655710      PMCID: PMC500460          DOI: 10.1136/jcp.49.4.324

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor.

Authors:  S R Prahalada; K P Keenan; P R Hertzog; L R Gordon; C P Peter; K A Soper; M J van Zwieten; D L Bokelman
Journal:  Urology       Date:  1994-05       Impact factor: 2.649

2.  Etiology of benign prostatic hyperplasia.

Authors:  J T Isaacs
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

3.  Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.

Authors:  R M Tuttle; S Loop; R E Jones; A W Meikle; R C Ostenson; S R Plymate
Journal:  Prostate       Date:  1994-05       Impact factor: 4.104

4.  TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin.

Authors:  P Russo; J A Warner; R Huryk; G Perez; W D Heston
Journal:  Prostate       Date:  1994-05       Impact factor: 4.104

5.  Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.

Authors:  P E Juniewicz; S J Hoekstra; B M Lemp; T A Barbolt; J A Devin; E Gauthier; G Frenette; J Y Dube; R R Tremblay
Journal:  Endocrinology       Date:  1993-08       Impact factor: 4.736

6.  The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.

Authors:  E Shapiro; V Hartanto; H Lepor
Journal:  Prostate       Date:  1992       Impact factor: 4.104

Review 7.  Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology.

Authors:  R Montironi; C M Magi Galluzzi; S Marina; L Diamanti
Journal:  J Cell Biochem Suppl       Date:  1994

8.  Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.

Authors:  A Tewari; K Shinohara; P Narayan
Journal:  Urology       Date:  1995-02       Impact factor: 2.649

9.  Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.

Authors:  S M Cohen; J G Werrmann; G H Rasmusson; W K Tanaka; P F Malatesta; S Prahalada; J G Jacobs; G Harris; T M Nett
Journal:  Prostate       Date:  1995-02       Impact factor: 4.104

10.  Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.

Authors:  R Montironi; C Magi-Galluzzi; G Muzzonigro; E Prete; M Polito; G Fabris
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

View more
  5 in total

1.  Prostate pathology case study seminar.

Authors:  R Montironi; E Alexander; D G Bostwick
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

2.  Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.

Authors:  Tyler M Bauman; Priyanka D Sehgal; Karen A Johnson; Thomas Pier; Reginald C Bruskewitz; William A Ricke; Wei Huang
Journal:  Prostate       Date:  2014-04-30       Impact factor: 4.104

3.  Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride.

Authors:  R Montironi; R Mazzucchelli; R Pomante; D Thompson; V Duval da Silva; L Vaught; P H Bartels
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

4.  5α-Reductase Isozymes in the Prostate.

Authors:  Yuan-Shan Zhu; Guang-Huan Sun
Journal:  J Med Sci       Date:  2005

5.  Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

Authors:  M Emberton; M Marberger; J de la Rosette
Journal:  Int J Clin Pract       Date:  2007-11-19       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.